PHARMACEUTICAL PUSH
Aspen targets more China partnerships
The pharmaceutical group’s ‘key’ offices in Beijing, Shanghai and Guangzhou now have all the necessary business licences
Aspen Holdings was considering entry into more partnerships in China to build critical mass in the country, management said in a presentation last week. The Durban-headquartered pharmaceutical group recently gained a foothold in China by taking over certain AstraZeneca and GlaxoSmithKline product lines. China was now home to Aspen’s largest regional sales force, with 650 staff in the country. Aspen has "key" offices in Beijing, Shanghai and Guangzhou and had secured all of its necessary business licences, the company said. "We are looking to bolster our product offering in China through developing a pipeline of products to launch and are already working on expanded offerings in both anaesthetics and in thrombosis," said Zihle Mgcokoca, Aspen’ investor relations manager. "As we develop our presence in China, we will explore the prospect of partnerships which allow us to accelerate our growth and provide greater reach and critical mass." In October, Aspen launched an infant-milk formu...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.